))
On Translating Aging, we talk with the worldwide community of researchers, entrepreneurs, and investors who are moving longevity science from the lab to the clinic. We bring you a commanding view of the entire field, in the words of the people and companies who are moving it forward today. The podcast is sponsored by BioAge labs, a clinical-stage biotechnology company developing therapies to extend human healthspan by targeting the molecular causes of aging.
…
continue reading
1
Partial epigenetic reprogramming: the "holy grail" for aging therapeutics (Michael Ringel, Life Biosciences)
37:57
37:57
Play later
Play later
Lists
Like
Liked
37:57
Michael Ringel is the Chief Operating Officer of Life Biosciences, a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. Michael became COO of Life just a few months ago, but he's been advising the company since 2018. Prior to this year, he was managing director and senior partner at B…
…
continue reading
1
Cell Reset Therapeutics to Extend Healthspan and Lifespan (Janine Sengstack, Junevity)
36:43
36:43
Play later
Play later
Lists
Like
Liked
36:43
Dr. Janine Sengstack is the Chief Scientific Officer and co-founder of Junevity, a company created in 2023 with the mission of extending health span and lifespan through what they term "Cell Reset therapeutics." The company recently secured $10 million in seed funding. In this episode, Chris and Janine explore the innovative platform Janine develop…
…
continue reading
1
Building the Infrastructure for Longevity Medicine: ARPA-H's PROSPR Program (Dr. Andrew Brack, Program Manager)
40:29
40:29
Play later
Play later
Lists
Like
Liked
40:29
Dr. Andrew Brack, Program Manager at the Advanced Research Projects Agency for Health (ARPA-H), discusses PROSPR (Proactive Solutions for Prolonging Resilience), an ambitious new program aimed at extending human healthspan. In this wide-ranging conversation, Chris and Andrew explore how PROSPR plans to accelerate the development of therapies that t…
…
continue reading
1
Decoding Stem Cell Rejuvenation Factors (Markus Gstöttner, CEO of Clock.bio)
26:46
26:46
Play later
Play later
Lists
Like
Liked
26:46
Markus Gstöttner is the CEO of Clock.bio, a company devoted to extending and improving the quality of life by reversing the harmful effects of time in our cells. In this episode, Gstöttner shares how his company is working to extend healthspan by understanding and harnessing the natural rejuvenation capabilities of stem cells. The conversation expl…
…
continue reading
1
Eliminating Pathogenic Cells to Treat Disease (Adam Freund & Remi Laberge, Arda Therapeutics)
45:51
45:51
Play later
Play later
Lists
Like
Liked
45:51
Adam Freund (CEO) and Remi Laberge (CTO) are the founders of Arda Therapeutics, a biotechnology company developing novel therapies that selectively eliminate harmful cell populations driving chronic diseases. In this episode, they discuss their innovative approach to treating conditions like idiopathic pulmonary fibrosis by identifying and removing…
…
continue reading
1
Precision Epigenetic Medicines to Extend Healthspan (Alex Aravanis, Moonwalk Biosciences)
42:04
42:04
Play later
Play later
Lists
Like
Liked
42:04
Alex Aravanis is the CEO and co-founder of Moonwalk Biosciences, a biotechnology company pioneering precision epigenetic medicines. In this episode, Chris and Alex discuss Moonwalk's innovative approach to developing a new class of medicines aimed at treating complex diseases and potentially extending human healthspan. The Finer Details: The concep…
…
continue reading
1
Hevolution: Extending Global Healthspan (Dr. Mehmood Khan, CEO)
43:14
43:14
Play later
Play later
Lists
Like
Liked
43:14
In this episode, Chris Patil speaks with Dr. Mehmood Khan, CEO of Hevolution Foundation, about the organization's mission to extend healthy human lifespan and better understand the aging process. Dr. Khan discusses Hevolution's unique approach to funding global scientific discovery and investing in private companies dedicated to advancing aging sci…
…
continue reading
1
Harnessing the Secretome to Combat Age-Related Immune Dysfunction (Dr. Hans Keirstead, Immunis)
47:38
47:38
Play later
Play later
Lists
Like
Liked
47:38
Hans Keirstead, PhD, is the Chairman of the Board at Immunis, a biotechnology company researching and developing immune secretome products to address age-driven immune deficits. In this episode, Chris and Hans discuss Immunis' approach to targeting the aging immune system as a key driver of age-related disease. They explore the potential of immune …
…
continue reading
1
Delaying menopause, extending healthspan: The promise of AMH-based therapeutics (Daisy Robinton, Oviva Therapeutics)
36:35
36:35
Play later
Play later
Lists
Like
Liked
36:35
Dr. Daisy Robinton, co-founder and CEO of Oviva Therapeutics, discusses the company's innovative approach to improving women's healthspan by targeting the biology of ovarian aging. Motivated by her personal experiences and the realization that female physiology is underserved by research and medicine, Daisy outlines how menopause is a key inflectio…
…
continue reading
1
Gene Therapies to Treat and Reverse Aging (Noah Davidsohn, Rejuvenate Bio)
35:14
35:14
Play later
Play later
Lists
Like
Liked
35:14
Dr. Noah Davidsohn, co-founder and CSO of Rejuvenate Bio, discusses the company's innovative work using gene therapies to treat age-related diseases in dogs and humans. In his conversation with host Chris Patil, he explains his recent groundbreaking study showing that partial cellular reprogramming with Yamanaka factors extended lifespan and health…
…
continue reading
1
30 Years of Aging Biology: A Pioneer's Perspective (Cynthia Kenyon, VP-Aging Research at Calico Labs)
44:06
44:06
Play later
Play later
Lists
Like
Liked
44:06
30 Years of Aging Biology: A Pioneer’s Perspective (Cynthia Kenyon - VP Aging Biology, Calico Labs) Dr. Cynthia Kenyon reflects on the evolution of the longevity field over the 30 years since the publication of her groundbreaking paper, “A C. elegans mutant that lives twice as long as wild type,” a genetic analysis of one of the first single-gene m…
…
continue reading
1
XPRIZE Healthspan: Catalyzing Therapies for Aging (Jamie Justice, PhD)
55:16
55:16
Play later
Play later
Lists
Like
Liked
55:16
Dr. Jamie Justice is Executive Director of the newly launched XPRIZE Healthspan, a $101 M international competition to accelerate therapeutics targeting aging biology. In conversation with host Chris Patil, Dr. Justice outlines the motivation, structure, and timeline of the prize, as well as how teams can get involved. She also explains unique aspe…
…
continue reading
1
"How We Age: The Science of Longevity" (Professor Coleen Murphy, Princeton)
36:33
36:33
Play later
Play later
Lists
Like
Liked
36:33
Dr. Coleen Murphy is a prominent aging researcher and author of the upcoming book “How We Age: The Science of Longevity” from Princeton University Press. In this wide-ranging discussion, Coleen provides insights into her motivation for writing this book, key topics covered, and her unique perspective on the field. Key ideas: Addressing ethical conc…
…
continue reading
1
From Startup to Acquisition (Nick Hertz, Mitokinin)
41:59
41:59
Play later
Play later
Lists
Like
Liked
41:59
Dr. Nicholas Hertz is the co-founder and former CSO of Mitokinin, a biotech company developing therapies targeting damaged mitochondria in neurodegenerative disease. Mitokinin was recently acquired by pharmaceutical giant AbbVie. In this episode, Nick recounts the journey from academic research on PINK1 biology to founding a startup and advancing a…
…
continue reading
1
Catalyzing moonshots in longevity biotech (Alex Colville, Age1)
40:34
40:34
Play later
Play later
Lists
Like
Liked
40:34
Dr. Alex Colville is the co-founder and General Partner of Age1 Ventures, a recently launched VC firm focused on funding contrarian, founder-led biotech companies aiming to extend healthy human lifespan. In this episode, Alex outlines Age1's thesis of identifying and empowering talented founders with ambitious visions for the longevity field. He sh…
…
continue reading
1
Reversing Skin Aging at the Cellular Level (Carolina Reis Oliveira and Alessandra Zonari, OneSkin)
35:51
35:51
Play later
Play later
Lists
Like
Liked
35:51
Dr. Carolina Reis Oliveira and Dr. Alessandra Zonari are the co-founders of OneSkin, a company developing science-backed skincare products to reverse skin aging at the cellular level. In this episode, Carolina and Alessandra tell host Dr. Chris Patil how OneSkin is leveraging recent advances in longevity science to create novel peptides that target…
…
continue reading
1
Discovering New Senolytics with Neural Networks (Felix Wong, Integrated Biosciences)
37:01
37:01
Play later
Play later
Lists
Like
Liked
37:01
Dr. Felix Wong is a co-founder of Integrated Biosciences, an early-stage biotech company developing next-generation therapeutics for cellular rejuvenation. He is also a postdoc at MIT and the Broad Institute and was a lead author on a recent Nature Aging paper describing the use of graph neural networks to discover new senolytic compounds. In this …
…
continue reading
1
“Taking disease by sTORm”: Developing Rapalogs to Extend Healthy Lifespan (Joan Mannick, Tornado Therapeutics)
29:16
29:16
Play later
Play later
Lists
Like
Liked
29:16
Joan Mannick, CEO and co-Founder of Tornado Therapeutics, joins the podcast to discuss her company’s exciting mission of developing a new generation of rapalog compounds specifically targeting the TORC1 complex. Rapalogs are analogs of the natural compound rapamycin, which has been shown to extend lifespan and healthspan in animal models by inhibit…
…
continue reading
1
Discovering Healthspan Interventions through Phenotype-Based Drug Screening (Mitchell Lee, Ora Biomedical)
32:16
32:16
Play later
Play later
Lists
Like
Liked
32:16
Mitchell Lee is the CEO and co-founder of Ora Biomedical, a Seattle-based biotech company using large-scale phenotypic drug screening in C. elegans to discover small molecule therapeutics that extend lifespan and healthspan. In this episode, Chris and Mitch discuss Ora's approach to drug discovery, which focuses on function and phenotype rather tha…
…
continue reading
1
Synergizing Synbio & Longevity: A Panel Discussion at SynBioBeta 2023
42:31
42:31
Play later
Play later
Lists
Like
Liked
42:31
This special episode features a panel discussion moderated by Chris Patil at the 2023 SynBioBeta conference. The panel brings together leaders from the synthetic biology and longevity communities to explore opportunities for collaboration and cross-pollination between these fields. Panelists discuss the talent bottleneck in longevity research, chal…
…
continue reading
1
Nurturing the Next Generation of Leaders in Aging Biology (Dr. Courtney Hudson-Paz, Time Initiative)
22:50
22:50
Play later
Play later
Lists
Like
Liked
22:50
In this episode of Translating Aging, host Chris Patil is joined by Dr. Courtney Hudson-Paz, the Founder and Program Director of the Time Initiative, an organization whose mission is to build a network of undergraduate leaders in aging biology. Courtney takes us on a journey into the world of aging biology and the mission of the Time Initiative, hi…
…
continue reading
1
Epigenetic Reprogramming Therapies to Extend Healthspan (Dr. Jacob Kimmel, Head of Research, NewLimit)
40:25
40:25
Play later
Play later
Lists
Like
Liked
40:25
Jacob Kimball is the Head of Research and co-founder of NewLimit, a company aiming to develop epigenetic reprogramming therapies to treat age-related diseases and extend human healthspan. In this episode, Chris and Jacob have an in-depth discussion about NewLimit’s mission and approach. They explore how NewLimit is leveraging epigenetics and machin…
…
continue reading
1
A New Approach for Cardiovascular Disease (Dr. Matthew O’Connor, Cyclarity Therapeutics)
37:52
37:52
Play later
Play later
Lists
Like
Liked
37:52
In today’s episode, Chris is joined by Dr. Matthew "Oki" O'Connor, CEO for Scientific Affairs at Cyclarity Therapeutics, a company focused on eliminating arterial plaque, a prevalent issue in old age. Dr. O'Connor shares his insights on the causes and effects of atherosclerosis, the leading cause of death worldwide, and how aging contributes to pla…
…
continue reading
1
Targeting Pathologic Cells to Preserve Biological Youth (Dr. Marco Quarta, Rubedo Life Sciences)
40:59
40:59
Play later
Play later
Lists
Like
Liked
40:59
Dr. Marco Quarta, CEO and Co-founder of Rubedo Life Sciences, joins Chris on today’s episode to discuss his company’s strategy of targeting pathologic cells to develop therapeutics for chronic degenerative conditions. The conversation covers the evolving definition of senescence and the challenges of identifying and classifying pathologic cells, wh…
…
continue reading
1
Bone Marrow Banking for Cell Therapy Material at Scale (Kevin Caldwell, Ossium Health)
41:20
41:20
Play later
Play later
Lists
Like
Liked
41:20
In today’s episode, Chris sits down with Kevin Caldwell, CEO, Co-Founder, and President of Ossium Health, a company that aims to improve human health and longevity through bioengineering - specifically using stem cell science to create materials for cell therapies. Together, they discuss Ossium’s approach: processing and banking of bone marrow from…
…
continue reading
